WAVE Life Sciences Ltd. $WVE Shares Sold by Emerald Advisers LLC

Emerald Advisers LLC lowered its position in shares of WAVE Life Sciences Ltd. (NASDAQ:WVE) by 8.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 2,996,900 shares of the company’s stock after selling 260,219 shares during the period. Emerald Advisers LLC owned 1.88% of WAVE Life Sciences worth $21,937,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. boosted its stake in WAVE Life Sciences by 20.0% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company’s stock valued at $97,607,000 after purchasing an additional 2,500,000 shares during the period. 683 Capital Management LLC raised its holdings in shares of WAVE Life Sciences by 4.5% during the second quarter. 683 Capital Management LLC now owns 4,100,000 shares of the company’s stock valued at $26,650,000 after buying an additional 175,000 shares during the last quarter. Loomis Sayles & Co. L P raised its holdings in shares of WAVE Life Sciences by 35.3% during the second quarter. Loomis Sayles & Co. L P now owns 3,295,700 shares of the company’s stock valued at $21,422,000 after buying an additional 859,160 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of WAVE Life Sciences by 6.4% during the second quarter. Geode Capital Management LLC now owns 2,759,381 shares of the company’s stock worth $17,938,000 after buying an additional 166,982 shares during the period. Finally, Affinity Asset Advisors LLC grew its holdings in WAVE Life Sciences by 9.6% in the 2nd quarter. Affinity Asset Advisors LLC now owns 2,000,308 shares of the company’s stock worth $13,002,000 after buying an additional 175,308 shares in the last quarter. 89.73% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CFO Kyle Moran sold 210,000 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $14.77, for a total value of $3,101,700.00. Following the sale, the chief financial officer directly owned 89,218 shares in the company, valued at $1,317,749.86. The trade was a 70.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Chris Francis sold 441,031 shares of WAVE Life Sciences stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $14.57, for a total transaction of $6,425,821.67. Following the completion of the transaction, the insider owned 25,000 shares in the company, valued at approximately $364,250. This trade represents a 94.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 912,117 shares of company stock worth $13,464,044. 23.98% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

WVE has been the topic of several recent analyst reports. Oppenheimer lifted their target price on WAVE Life Sciences from $24.00 to $32.00 and gave the company an “outperform” rating in a research note on Tuesday, December 16th. Wall Street Zen raised WAVE Life Sciences from a “sell” rating to a “hold” rating in a research note on Sunday, January 11th. Weiss Ratings restated a “sell (d-)” rating on shares of WAVE Life Sciences in a research note on Wednesday, October 8th. Leerink Partners reaffirmed an “outperform” rating on shares of WAVE Life Sciences in a report on Monday, December 8th. Finally, Wedbush increased their target price on shares of WAVE Life Sciences from $20.00 to $33.00 and gave the company an “outperform” rating in a research report on Friday, December 12th. Thirteen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $31.67.

WAVE Life Sciences Stock Up 0.9%

Shares of WAVE Life Sciences stock opened at $13.94 on Thursday. The business has a fifty day simple moving average of $13.16 and a 200-day simple moving average of $9.81. WAVE Life Sciences Ltd. has a fifty-two week low of $5.28 and a fifty-two week high of $21.73. The firm has a market cap of $2.33 billion, a price-to-earnings ratio of -18.59 and a beta of -1.82.

WAVE Life Sciences (NASDAQ:WVE) last released its earnings results on Monday, November 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). WAVE Life Sciences had a negative return on equity of 75.61% and a negative net margin of 111.64%.The firm had revenue of $7.61 million for the quarter, compared to analyst estimates of $9.85 million. Analysts anticipate that WAVE Life Sciences Ltd. will post -1.14 earnings per share for the current fiscal year.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.